Assessment of pre-existing anti-drug antibody (preADA) reactivity at early drug development stages can be beneficial for candidate selection. We investigated the applicability of a generic immune-complex anti-drug antibody (ADA) assay for early preADA assessment as an easily available alternative to the commonly used ADA bridging assay. The results confirmed the expected assay difference regarding isotype detectability. Tested drug candidates were identified as preADA-reactive using the immune-complex ADA assay despite its limitation of not being able to detect IgM-type preADAs. We recommend a purpose-driven use of the two assay formats. For the purpose of ranking different Pro329Gly mutation-bearing drug candidates, the immune-complex ADA assay is preferred in the phase before selecting a drug for clinical development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4155/bio-2022-0085 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of oral health literacy in demand for oral healthcare services for missing teeth replacement among dental patients visiting a dental teaching hospital in India.
J Indian Prosthodont Soc
January 2025
Department of Substitutive Dental Sciences, College of Dentistry and Pharmacy, Buraydah Private Colleges, Buraydah, Saudi Arabia.
Aims: To assess the role of oral health literacy (OHL) in demand for oral healthcare services for missing teeth replacement among adult patients who are visiting the outpatient department of a teaching hospital, Andhra Pradesh, India.
Settings And Design: This cross-sectional study was conducted in a dental teaching institute, Andhra Pradesh, southern part of India.
Materials And Methods: Based on the inclusion and exclusion criteria, a sample of adult participants was selected through systematic random method from the patients who visited the outpatient department.
Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile.
Front Immunol
January 2025
Polpharma Biologics S.A., Gdansk, Poland.
Background: Biosimilar natalizumab (biosim-NTZ) is the first biosimilar monoclonal antibody of reference natalizumab (ref-NTZ) for treatment of relapsing forms of multiple sclerosis (MS). Within the totality of evidence for demonstration of biosimilarity, immunogenicity assessments were performed in healthy subjects and patients with relapsing-remitting MS (RRMS) to confirm a matching immunogenicity profile between biosim-NTZ and ref-NTZ.
Methods: Immunogenicity of biosim-NTZ versus ref-NTZ was evaluated in two pivotal clinical studies.
A Novel Differentiation Nomogram Model for Brucellar Spondylitis and Tuberculous Spondylitis.
Infect Drug Resist
December 2024
Department of Spine Surgery, The First People's Hospital of Kashi Prefecture, Kashi, Xinjiang, 844000, People's Republic of China.
Background: Tuberculous spondylitis (TS) and brucellar spondylitis (BS) exhibit certain similarities in clinical presentation and imaging characteristics, making differential diagnosis challenging. Developing a reliable differential diagnosis model can assist clinicians in distinguishing between these two conditions at an early stage, allowing for targeted prevention and treatment strategies.
Methods: Patients diagnosed with TS and BS were retrospectively collected and randomized into training and validation cohorts (ratio 7:3).
Machine learning-based analysis of microfluidic device immobilized C. elegans for automated developmental toxicity testing.
Sci Rep
January 2025
vivoVerse, LLC, Austin, TX, 78731, USA.
Developmental toxicity (DevTox) tests evaluate the adverse effects of chemical exposures on an organism's development. Although current testing primarily relies on large mammalian models, the emergence of new approach methodologies (NAMs) is encouraging industries and regulatory agencies to evaluate novel assays. C.
View Article and Find Full Text PDFRuthenium-Hydride Complexes Facilitated Sustainable Synthesis of Isoxazolones via Acceptorless Dehydrogenative Annulation of Alcohols.
J Org Chem
January 2025
Centre for Organometallic Chemistry, School of Chemistry, Bharathidasan University, Tiruchirappalli 620 024, India.
A streamlined strategy for the one-pot synthesis of isoxazolone analogues has been developed through an acceptorless dehydrogenative annulation (ADA) pathway by employing new Ru(II) hydride complexes as effective catalysts. New Ru(II) complexes () tailored with N̂O chelating carbazolone benzhydrazone ligands were synthesized and their formation was confirmed using analytical and spectral techniques including FT-IR and NMR. The structural configuration of the complexes featuring an octahedral geometry around the Ru(II) ion was precisely determined by single-crystal X-ray diffraction analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!